Table 1.
Patient characteristics of the intestinal-type esophagogastric adenocarcinomas
| Number of patients | n (%) |
|---|---|
| All | 190 |
| Median age at diagnosis (range) | 74.4 (32.9–90.9) |
| Patient sex | |
| Female | 68 (35.8) |
| Male | 122 (64.2) |
| Site of primary tumor | |
| Distal oesophagus | 19 (10.0) |
| GOJ/cardia | 60 (31.6) |
| Corpus | 52 (27.4) |
| Antrum/pylorus | 59 (31.1) |
| Tumor differentiation grade | |
| Grade 1 | 17 (8.9) |
| Grade 2 | 93 (48.9) |
| Grade 3 | 80 (42.1) |
| Stage | |
| I | 40 (21.1) |
| II | 79 (41.6) |
| III | 61 (32.1) |
| IV | 10 (5.3) |
| Follow-up status | |
| Alive and free of disease | 34 (17.9) |
| Alive with disease | 1 (0.5) |
| Deceased | 155 (81.6) |
| Molecular subtypesa | |
| EBV + | 17 (9.1)b |
| MMR-D | 19 (10.2) |
| TP53 aberrant | 103 (55.4) |
| Others | 52 (28.0) |
aMMR-D mismatch repair deficient, MMR-P mismatch repair proficient, EBV Epstein–Barr virus
bThe groups were not mutually exclusive. The percentages are calculated as a proportion of the 186/190 tumors eligible for molecular characterization